1. Academic Validation
  2. Heterobifunctional Ligase Recruiters Enable pan-Degradation of Inhibitor of Apoptosis Proteins

Heterobifunctional Ligase Recruiters Enable pan-Degradation of Inhibitor of Apoptosis Proteins

  • J Med Chem. 2023 Apr 13;66(7):4703-4733. doi: 10.1021/acs.jmedchem.2c01817.
Yuen Lam Dora Ng 1 Aleša Bricelj 2 Jacqueline A Jansen 1 Arunima Murgai 1 3 Kirsten Peter 1 Katherine A Donovan 4 5 Michael Gütschow 6 Jan Krönke 1 3 Christian Steinebach 6 Izidor Sosič 2
Affiliations

Affiliations

  • 1 Department of Hematology, Oncology and Cancer Immunology, Charité─Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, D-12203 Berlin, Germany.
  • 2 Faculty of Pharmacy, University of Ljubljana, Aškerčeva Cesta 7, SI-1000 Ljubljana, Slovenia.
  • 3 German Cancer Consortium (DKTK) Partner Site Berlin and German Cancer Research Center (DKFZ), D-69120 Heidelberg, Germany.
  • 4 Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States.
  • 5 Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts 02215, United States.
  • 6 Phamaceutical Institute, Department of Pharmaceutical & Medicinal Chemistry, University of Bonn, An der Immenburg 4, D-53121 Bonn, Germany.
Abstract

Proteolysis targeting chimeras (PROTACs) represent a new pharmacological modality to inactivate disease-causing proteins. PROTACs operate via recruiting E3 ubiquitin ligases, which enable the transfer of ubiquitin tags onto their target proteins, leading to proteasomal degradation. However, several E3 Ligases are validated pharmacological targets themselves, of which inhibitor of Apoptosis (IAP) proteins are considered druggable in Cancer. Here, we report three series of heterobifunctional PROTACs, which consist of an IAP antagonist linked to either von Hippel-Lindau- or cereblon-recruiting ligands. Hijacking E3 Ligases against each other led to potent, rapid, and preferential depletion of cellular IAPs. In addition, these compounds caused complete X-chromosome-linked IAP knockdown, which was rarely observed for monovalent and homobivalent IAP antagonists. In cellular assays, hit degrader 9 outperformed antagonists and showed potent inhibition of Cancer cell viability. The hetero-PROTACs disclosed herein are valuable tools to facilitate studies of the biological roles of IAPs and will stimulate further efforts toward E3-targeting therapies.

Figures
Products